New CEO for Global Kinetics Corporation

Latest News

Australian medical technology company Global Kinetics Corporation (GKC) has announced the appointment of US-based Timothy I. Still as its new president and CEO.

Mr Still joins the company at a time of rapid growth, significantly driven by rising demand for its product, the Parkinson’s Kinetigraph (PKG). The company said its PKG system is now being used to improve the management of Parkinson’s disease in 200 key movement disorder clinics across the US, Europe and the Asia Pacific.

Mr Still will be based in San Francisco, which the company said was  consistent with its strategy to grow its presence in the US and other international markets.

GKC director and managing director of Brandon Capital, Dr Chris Nave, said, “Tim brings a wealth of experience in healthcare and medical diagnostics to GKC. Over the past decade, Tim has successively led a number of medical technology companies, and has been responsible for building these companies into commercially viable entities. A number of them have achieved attractive exits and investor returns. He brings a unique skill-set and proven history of commercialisation which matches perfectly with GKC’s rapidly expanding sales and growth strategy.”

Mr Still’s background includes over 26 years of experience in healthcare and medical diagnostics. He has extensive experience in designing and implementing highly focused commercial and business development strategies in both large and small companies. 

“I was initially drawn to GKC’s clear vision to have a measurable impact in Parkinson’s disease,” said Mr Still. “GKC’s product portfolio is first class and, combined with an impressive IP position and notable market demand, provides a compelling opportunity for near term commercial success.

“The market in digital health for diagnostic wearables is an exciting space, and I look forward to leading the team at GKC.”

Mr Nave thanked GKC’s interim leadership team, saying, “GKC has been lucky to be under the outstanding stewardship of Professor Mal Horne MD, company co-founder and chief scientific officer, during the course of the search for a new CEO. Mal has led the company through a period of increasing sales and revenue diversification, while remaining steadfastly focused on what it means to make a difference for people with Parkinson’s."